Cumberland Pharmaceuticals Inc. (CPIX)
USD 4.19
(3.2%)
USD 4.19
(3.2%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 12.78 Million USD | -38.5% |
| 2022 | 20.78 Million USD | 37.75% |
| 2021 | 15.09 Million USD | -6.04% |
| 2020 | 16.05 Million USD | -21.95% |
| 2019 | 20.57 Million USD | 2.88% |
| 2018 | 20 Million USD | 104.08% |
| 2017 | 9.8 Million USD | 139.02% |
| 2016 | 4.1 Million USD | 141.18% |
| 2015 | 1.7 Million USD | 0.0% |
| 2014 | - USD | 0.0% |
| 2013 | - USD | -100.0% |
| 2012 | 4.35 Million USD | -19.83% |
| 2011 | 5.43 Million USD | 6.4% |
| 2010 | 5.11 Million USD | -53.32% |
| 2009 | 10.94 Million USD | 96.35% |
| 2008 | 5.57 Million USD | 508.29% |
| 2007 | 916.66 Thousand USD | -74.37% |
| 2006 | 3.57 Million USD | 0.0% |
| 2005 | - USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 16.08 Million USD | 25.81% |
| 2024 Q2 | 16.09 Million USD | 0.05% |
| 2023 Q4 | 12.78 Million USD | -30.19% |
| 2023 Q3 | 18.31 Million USD | -1.68% |
| 2023 Q1 | 20.62 Million USD | -0.79% |
| 2023 Q2 | 18.62 Million USD | -9.68% |
| 2023 FY | 12.78 Million USD | -38.5% |
| 2022 FY | 20.78 Million USD | 37.75% |
| 2022 Q1 | 20.02 Million USD | 32.69% |
| 2022 Q2 | 19 Million USD | -5.11% |
| 2022 Q3 | 17.7 Million USD | -6.84% |
| 2022 Q4 | 20.78 Million USD | 17.44% |
| 2021 FY | 15.09 Million USD | -6.04% |
| 2021 Q2 | 14.51 Million USD | -8.09% |
| 2021 Q4 | 15.09 Million USD | -0.92% |
| 2021 Q1 | 15.78 Million USD | -1.68% |
| 2021 Q3 | 15.22 Million USD | 4.94% |
| 2020 Q3 | 16.32 Million USD | -12.14% |
| 2020 Q4 | 16.05 Million USD | -1.62% |
| 2020 FY | 16.05 Million USD | -21.95% |
| 2020 Q1 | 20.33 Million USD | -1.19% |
| 2020 Q2 | 18.58 Million USD | -8.61% |
| 2019 FY | 20.57 Million USD | 2.88% |
| 2019 Q4 | 20.57 Million USD | 2.88% |
| 2019 Q2 | 20 Million USD | 0.0% |
| 2019 Q3 | 20 Million USD | 0.0% |
| 2019 Q1 | 20 Million USD | 0.0% |
| 2018 FY | 20 Million USD | 104.08% |
| 2018 Q1 | 12 Million USD | 22.45% |
| 2018 Q3 | 12 Million USD | 0.0% |
| 2018 Q4 | 20 Million USD | 66.67% |
| 2018 Q2 | 12 Million USD | 0.0% |
| 2017 FY | 9.8 Million USD | 139.02% |
| 2017 Q2 | 6.7 Million USD | 63.41% |
| 2017 Q1 | 4.1 Million USD | 0.0% |
| 2017 Q4 | 9.8 Million USD | 22.5% |
| 2017 Q3 | 8 Million USD | 19.4% |
| 2016 Q1 | 1.7 Million USD | 0.0% |
| 2016 FY | 4.1 Million USD | 141.18% |
| 2016 Q3 | 3.7 Million USD | 5.71% |
| 2016 Q2 | 3.5 Million USD | 105.88% |
| 2016 Q4 | 4.1 Million USD | 10.81% |
| 2015 Q2 | 1.7 Million USD | 0.0% |
| 2015 FY | 1.7 Million USD | 0.0% |
| 2015 Q4 | 1.7 Million USD | 0.0% |
| 2015 Q3 | 1.7 Million USD | 0.0% |
| 2015 Q1 | - USD | 0.0% |
| 2014 Q2 | - USD | 0.0% |
| 2014 Q1 | - USD | 0.0% |
| 2014 Q3 | - USD | 0.0% |
| 2014 FY | - USD | 0.0% |
| 2014 Q4 | - USD | 0.0% |
| 2013 Q2 | 5.85 Million USD | 34.4% |
| 2013 Q3 | 4.85 Million USD | -17.06% |
| 2013 Q4 | - USD | -100.0% |
| 2013 FY | - USD | -100.0% |
| 2013 Q1 | 4.35 Million USD | 0.0% |
| 2012 Q3 | 4.94 Million USD | 13.39% |
| 2012 Q4 | 4.35 Million USD | -11.81% |
| 2012 FY | 4.35 Million USD | -19.83% |
| 2012 Q1 | 6.55 Million USD | 34.98% |
| 2012 Q2 | 4.35 Million USD | -33.54% |
| 2011 Q2 | 602.09 Thousand USD | -76.93% |
| 2011 Q4 | 4.85 Million USD | -5.97% |
| 2011 Q3 | 5.16 Million USD | 758.39% |
| 2011 FY | 5.43 Million USD | 6.4% |
| 2011 Q1 | 2.61 Million USD | -41.9% |
| 2010 FY | 5.11 Million USD | -53.32% |
| 2010 Q2 | 7.97 Million USD | -15.59% |
| 2010 Q1 | 9.44 Million USD | -13.73% |
| 2010 Q3 | 5.37 Million USD | -32.64% |
| 2010 Q4 | 4.49 Million USD | -16.35% |
| 2009 Q1 | 5.54 Million USD | -0.55% |
| 2009 Q3 | 15.5 Million USD | 226.96% |
| 2009 Q2 | 4.74 Million USD | -14.47% |
| 2009 Q4 | 10.94 Million USD | -29.39% |
| 2009 FY | 10.94 Million USD | 96.35% |
| 2008 Q4 | 5.57 Million USD | 0.0% |
| 2008 Q3 | - USD | 0.0% |
| 2008 Q1 | 458.32 Thousand USD | -50.0% |
| 2008 Q2 | - USD | -100.0% |
| 2008 FY | 5.57 Million USD | 508.29% |
| 2007 Q3 | 1.37 Million USD | -25.0% |
| 2007 FY | 916.66 Thousand USD | -74.37% |
| 2007 Q2 | 1.83 Million USD | -41.19% |
| 2007 Q1 | 3.11 Million USD | -12.82% |
| 2007 Q4 | 916.66 Thousand USD | -33.33% |
| 2006 Q4 | 3.57 Million USD | 0.0% |
| 2006 FY | 3.57 Million USD | 0.0% |
| 2005 FY | - USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 489.96 Million USD | 97.391% |
| Embecta Corp. | 1.62 Billion USD | 99.213% |
| ANI Pharmaceuticals, Inc. | 309.66 Million USD | 95.872% |
| Dynavax Technologies Corporation | 252.41 Million USD | 94.935% |
| Esperion Therapeutics, Inc. | 501.54 Million USD | 97.451% |
| Pacira BioSciences, Inc. | 513.79 Million USD | 97.512% |
| PainReform Ltd. | 30 Thousand USD | -42513.813% |
| Aquestive Therapeutics, Inc. | 91.07 Million USD | 85.963% |
| Sunshine Biopharma, Inc. | 539.03 Thousand USD | -2271.672% |
| SCYNEXIS, Inc. | 12.15 Million USD | -5.141% |
| China SXT Pharmaceuticals, Inc. | 117.12 Thousand USD | -10814.585% |
| Cosmos Health Inc. | 3.03 Million USD | -321.177% |
| Journey Medical Corporation | 14.62 Million USD | 12.569% |
| Sunshine Biopharma, Inc. | 539.03 Thousand USD | -2271.672% |
| Safety Shot Inc | 304.9 Thousand USD | -4092.801% |
| Alpha Teknova, Inc. | 13.25 Million USD | 3.523% |
| Intra-Cellular Therapies, Inc. | 13.32 Million USD | 4.066% |
| Bright Green Corporation | 201.78 Thousand USD | -6235.59% |
| Procaps Group, S.A. | 28.41 Million USD | 55.001% |
| Theratechnologies Inc. | 51.26 Million USD | 75.061% |
| Harrow Health, Inc. | 183.17 Million USD | 93.021% |
| Sonoma Pharmaceuticals, Inc. | 87 Thousand USD | -14594.418% |
| Biofrontera Inc. | 804 Thousand USD | -1490.068% |
| DURECT Corporation | 2.7 Million USD | -373.136% |
| Supernus Pharmaceuticals, Inc. | 33.19 Million USD | 61.489% |
| Cronos Group Inc. | 1.55 Million USD | -720.022% |
| OptiNose, Inc. | 611 Thousand USD | -1992.331% |
| Ironwood Pharmaceuticals, Inc. | 498.3 Million USD | 97.434% |
| Kala Pharmaceuticals, Inc. | 34.19 Million USD | 62.609% |
| RedHill Biopharma Ltd. | 455 Thousand USD | -2709.702% |
| Organogenesis Holdings Inc. | 60.74 Million USD | 78.954% |
| Guardion Health Sciences, Inc. | - USD | -Infinity% |
| Radius Health, Inc. | 339.66 Million USD | 96.236% |
| Universe Pharmaceuticals INC | - USD | -Infinity% |
| ProPhase Labs, Inc. | 10.25 Million USD | -24.626% |
| Phibro Animal Health Corporation | 458.28 Million USD | 97.21% |
| Procaps Group S.A. | 28.41 Million USD | 55.001% |
| Alvotech | 1.02 Billion USD | 98.756% |
| TherapeuticsMD, Inc. | 6.53 Million USD | -95.716% |
| Viatris Inc. | 16.18 Billion USD | 99.921% |
| Rockwell Medical, Inc. | 8.29 Million USD | -54.156% |
| Aytu BioPharma, Inc. | 10.87 Million USD | -17.534% |
| SIGA Technologies, Inc. | 335.99 Thousand USD | -3704.907% |
| Tilray Brands, Inc. | 287.93 Million USD | 95.56% |
| Lifecore Biomedical, Inc. | 120.51 Million USD | 89.392% |
| Shineco, Inc. | 10.01 Million USD | -27.62% |
| PetIQ, Inc. | 437.82 Million USD | 97.08% |
| Regencell Bioscience Holdings Limited | - USD | -Infinity% |
| Incannex Healthcare Limited | 210 Thousand USD | -5987.688% |
| Neurocrine Biosciences, Inc. | 258.3 Million USD | 95.051% |
| Alimera Sciences, Inc. | 64.48 Million USD | 80.176% |
| Silver Spike Investment Corp. | - USD | -Infinity% |
| Assertio Holdings, Inc. | 38.51 Million USD | 66.807% |
| Shuttle Pharmaceuticals Holdings, Inc. | 135.08 Thousand USD | -9363.497% |
| Petros Pharmaceuticals, Inc. | 6.85 Million USD | -86.429% |
| Clever Leaves Holdings Inc. | 720 Thousand USD | -1675.576% |
| Cyclo Therapeutics, Inc. | 22.48 Thousand USD | -56758.851% |
| Avadel Pharmaceuticals plc | 32.75 Million USD | 60.976% |
| Hempacco Co., Inc. | 5.93 Million USD | -115.548% |
| Talphera, Inc. | - USD | -Infinity% |
| Alvotech | 1.02 Billion USD | 98.756% |
| Eagle Pharmaceuticals, Inc. | 56.21 Million USD | 77.259% |
| Lantheus Holdings, Inc. | 616.12 Million USD | 97.925% |
| Currenc Group, Inc. | 2.5 Million USD | -409.943% |
| Kamada Ltd. | 7.43 Million USD | -71.876% |
| Indivior PLC | 235.66 Million USD | 94.575% |
| Evoke Pharma, Inc. | 5 Million USD | -155.683% |
| Flora Growth Corp. | 942 Thousand USD | -1257.128% |
| Cyclo Therapeutics, Inc. | 22.48 Thousand USD | -56758.851% |
| Evolus, Inc. | 120.35 Million USD | 89.378% |
| HUTCHMED (China) Limited | 48.18 Million USD | 73.471% |
| Amphastar Pharmaceuticals, Inc. | 589.19 Million USD | 97.83% |
| Akanda Corp. | 2.49 Million USD | -411.948% |